Influence of provider factors and race on uptake of breast cancer gene expression profiling.

about

Influence of provider factors and race on uptake of breast cancer gene expression profiling.

Item

http://www.wikidata.org/entity/Q48234815

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Influence of provider factors ...... cer gene expression profiling.

@en

Influence of provider factors ...... cer gene expression profiling.

@nl

type

Item

label

Influence of provider factors ...... cer gene expression profiling.

@en

Influence of provider factors ...... cer gene expression profiling.

@nl

prefLabel

Influence of provider factors ...... cer gene expression profiling.

@en

Influence of provider factors ...... cer gene expression profiling.

@nl

P1476

Influence of provider factors ...... ncer gene expression profiling

@en

P2093

Anne-Marie Meyer

http://www.w3.org/2001/XMLSchema#string

Christopher D Baggett

http://www.w3.org/2001/XMLSchema#string

Ke Meng

http://www.w3.org/2001/XMLSchema#string

Lisa A Carey

http://www.w3.org/2001/XMLSchema#string

Stephanie B Wheeler

http://www.w3.org/2001/XMLSchema#string

Xi Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Racial variation in breast cancer treatment among Department of Defense beneficiaries.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Implementing the Institute of Medicine definition of disparities: an application to mental health care.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

P304

1743-1751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.31222

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Megan C Roberts

Katherine E Reeder-Hayes

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29338090

http://www.w3.org/2001/XMLSchema#string